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Neonatal blockade of N-methyl-D-aspartic acid (NMDA) receptors represents one of experimental animal models for
schizophrenia. This study is to investigate the long-term brain-derived neurotrophic factor (BDNF) expression proﬁles in diﬀerent
regions and correlation with “schizophrenia-like” behaviors in the adolescence and adult of this rat model. The NMDA receptor
antagonist MK801 was administered to female Sprague-Dawley rats on postnatal days (PND) 5 through 14. Open-ﬁeld test
was performed on PND 42, and PND 77 to examine the validity of the current model. BDNF protein levels in hippocampus
and prefrontal cortex (PFC) were analyzed on PND 15, PND 42, and PND 77. Results showed that neonatal challenge with
MK-801 persistently elevated locomotor activity as well as BDNF expression; the alterations in BDNF expression varied at
diﬀerent developing stages and among brain regions. However, these ﬁndings provide neurochemical evidence that the blockade
of NMDA receptors during brain development results in long-lasting alterations in BDNF expression and might contribute to
neurobehavioral pathology of the present animal model for schizophrenia. Further study in the mechanisms and roles of the
BDNF may lead to better understanding of the pathophysiology of schizophrenia.
1.Introduction
Schizophrenia is a complex and severe brain disorder with
poorly deﬁned etiology and pathophysiology. Many diverse
lines of evidence indicate that schizophrenia is a neurode-
velopment disorder; early-life adverse events such as pre-
natal stress, obstetric complications, malnutrition, and viral
infection may interrupt the normal brain development and
increase the susceptibility of schizophrenia later in life [1–
4]. Neurotrophic molecules are believed to be critical in the
development and function maintenance of cortical neurons
and synapses, such as brain-derived neurotrophic factor
(BDNF) [5]. BDNF is a key member of the neurotrophin
family widely expressed in the brain [6, 7]; it plays an
important and unique role in regulating a wide repertoire
of functions at diﬀerent development stages, including neu-
ronal survival, migration, phenotypic diﬀerentiation, and
axonalanddendriticgrowthinneonatalindividuals[8,9],as
wellassynapticplasticityandbehaviorinadulthood[10–12].
Several lines of evidence have suggested the involvement
of BDNF in pathophysiology of schizophrenia in both
human and animal studies [13–15]. However, knowledge in
understandingofBDNFinpathophysiologyofschizophrenia
remains limited and poorly deﬁned. One of key pitfalls
of schizophrenia research in animal studies is that all
experiments usually focused only on a certain period during
development. Therefore, it is fundamentally and clinically
signiﬁcant to investigate long-term changes of BDNF in
animal models of schizophrenia in a development scheme.
Among a number of schizophrenia animal models,
repeated administration of dizocilpine maleate (MK-801, a
noncompetitive NMDA receptor antagonist) during neona-
tal period may be a suitable animal model to explore certain
remaining issues. This is because the paradigm of this model
has been shown to produce “schizophrenia-like” behaviors
weeks after administration [16], a potential advantage over
other models to study long-lasting eﬀects in a development
scheme. The aim of the present study is to investigate the2 Journal of Biomedicine and Biotechnology
long-term BDNF expression proﬁles in diﬀerent regions
and correlation with “schizophrenia-like” behaviors in the
adolescence and adult of this rat model.
2.MaterialsandMethods
2.1. Animals. Timed-pregnant Sprague-Dawley rats were
purchased from the Department of Laboratory Animal Sci-
ence, Peking University Health Science Center. Female pups
were collected and then cross-fostered to one of the lactating
dams within 24h of parturition, which was designated as
Postnatal day 0 (PND 0). Animals were housed on a 12:12
light/dark cycle (lights on 08:00 hour) with ad libitum
access to food and water. All procedures were performed in
accordance with the National Institute of Health Guide for
Use and Care of Laboratory Animals and were approved by
the Peking University Committee on Animal Care and Use.
On PND 5, the pups from each litter were randomly
assigned to the MK-801 or saline groups, which were
injected subcutaneously with MK-801 or saline for 10
c o n s e c u t i v ed a y s .A l lg r o u p sw e r es e xb a l a n c e d .T oa v o i d
potential inﬂuence on BDNF levels by behavioral testing,
BDNF assessment and behavioral testing were performed on
diﬀerent rats. For BDNF assessment, rats were sacriﬁced and
assessed for BDNF levels 24 hours (PND 15) and 4 weeks
(PND 42) after the last injection. For behavioral testing, all
animals were tested for locomotor activity at PND 42 and
PND 77. Pups (except those sacriﬁced on PND 15) were
weaned on PND 22 and then housed 4 per cage.
2.2. Drug Treatment. MK-801 was obtained from Sigma (St.
Louis, MO, USA) and dissolved in saline (0.9% NaCl). Based
on our preliminary experiment, a dose of 0.25mg/kg per
injection of MK-801 was used in the present study. All rats
received injections twice daily beginning at 9:00 and 15:00,
respectively.
2.3. Locomotor Activity. Because locomotor activity has been
thought to be an indicator of “schizophrenia-like” behavior
[17–19], to test the face validity of the MK-801 administra-
tion in mimicking schizophrenia, we measured locomotor
activity. Two tests on PD 42 and PD 77 for each animal
were conducted, of which the procedures were adapted from
our previous work [20]. Brieﬂy, locomotor activity was
measured by an automated video tracking system with four
activity chambers (DigBehv-LM4, Shanghai Jiliang Software
T e c h n o l o g yC o .L t d ,C h i n a ) .T h ec h a m b e r sw e r em a d eo f
black iron (45cm×45cm×70cm, length×width×height).
A monochrome video camera was mounted at the top of
each chamber. All of the chambers were connected to a PC
which recorded the locomotion of rat. The video documents
(stored in the computer) were analyzed by the DigBehv
analysis software. The analysis resulted in a track record, and
locomotor activity was expressed as a total distance traveled
for a predetermined period of time. On the testing day, rats
were kept in testing room at least for 60 minutes before
placing animals in the activity chambers. The locomotion
was recorded for 60 minutes each time.
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Figure 1: Neonatal MK-801 treatment increased the total locomo-
tor activity on both PND 42 and PND 77. ∗, P<. 05.
2.4. Measurement of BDNF Protein Levels. The BDNF Emax
ImmunoAssay system (Promega) was used to measure
BDNF protein levels in each brain region according to the
manufacturer’s protocol. Brieﬂy, on PN15 (24 hours after the
last injection) and PN42 (4 weeks after the last injection),
brain tissues of hippocampus and PFC were immediately
dissected out and frozen on dry ice. Then the dissected
brain tissues were homogenized in lysis buﬀer (137mm
NaCl, 20mm Tris, 1% NP-40 detergent, 10% glycerol,
1mm methylphenylsulphonylﬂuoride, 10mg/mL aprotinin,
1mg/mL leupeptin, and 0.5mm sodium orthovanadate).
Homogenates were centrifuged at 10,000rpm for 10min in
a cold room, and supernatants were used for ELISA analysis.
A standard curve was made using serial dilutions of known
amounts of BDNF ranging from 0 to 500pg/mL. Results for
duplicate experiments were averaged, and BDNF values were
corrected for the amount of protein in each sample. The
sensitivity of the assay was within the range reported by the
above-mentioned Promega kit and the interassay variation
was less than 10%.
2.5. Statistics. A l ld a t aw e r ee x p r e s s e da sm e a n s± S.E.M.
Statistical diﬀerences between groups were determined by
independentsamplest-test.AprobabilitylevelofP<. 05was
considered to be statistically signiﬁcant. Statistical analyses
were performed using SPSS 17 for windows.
3. Results
3.1. Locomotor Activity Were Elevated on PND 42 and PND
77. MK-801 treated rats exhibited signiﬁcantly increased
locomotor activity compared with saline-treated controls on
both PND 42 (t =− 2.63, df = 17, and P = .018) and PND
77 ( t =− 2.43, df = 20, and P = .025) (Figure 1).
3.2. Changes of BDNF Protein Expression in the PFC and
Hippocampus on PND 15, PND 42, and PND 77. Protein
content of BDNF was signiﬁcantly increased, but withJournal of Biomedicine and Biotechnology 3
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Figure 2: The inﬂuence of neonatal MK-801 treatment on BDNF
concentrations in (a) PFC and (b) hippocampus on diﬀerent post-
natal days. ∗, ∗∗, ∗∗∗P<. 05, P<. 01, P<. 001 respectively.
diﬀerent patterns in PFC and hippocampus. In PFC, the
BDNF expression was signiﬁcantly upregulated in MK-801
treated rats (t =− 6.19, df = 16, and P<. 001) at
early time point of PND 15. However, this early increase of
BDNF expression was only transient, and it went back to
normal control baseline on PND 42 (t =− 1.19, df = 19,
and P>. 05) and PND 77 (t =− 0.54, df = 17, and
P>. 05) (Figure 2(a)). In contrast to the developmental
pattern in PFC, BDNF expression in the hippocampus was
not inﬂuenced by neonatal MK-801 administration (t =
−0.30, df = 16, and P>. 05) on PND 15. However, there
was a signiﬁcant late increase of BDNF expression on PND
42 (t =− 3.89, df = 16.9, and P = .001) and PND 77
(t =− 3.28, df = 17, and P = .01) (Figure 2(b)).
4. Discussion
The major ﬁndings of present study are (1) exposure of
the developing brain to MK-801, neonatal blockade of
NMDA receptor, resulted in the locomotor hyperactivity in
adolescence and in adult of rats; (2) BDNF levels in brain
tissues were aﬀected by neonatal MK-801 administration
with patterns of age-dependent, long-lasting, and brain
regional speciﬁcity; (3) the postpubertal emergence of the
hippocampal BDNF upregulation was concomitant with
the behavioral abnormality of the animals. The above
ﬁndings altogether indicate that altered BDNF expression
in this experimental animal model for schizophrenia may
be correlated with the development of schizophrenia-like
behavior and pathophysiology.
It has been demonstrated that Schizophrenia is usu-
ally diagnosed during adolescence, a period experiencing
dramatic changes in behaviors [21]; interestingly BDNF
expression in human brain changes during development and
maturation [22]. Therefore it is necessary and important
to include diﬀerent time points in the current study. We
chose PFC and hippocampus in the current study, because
these two brain areas are most implicated in schizophrenia
[23, 24]. Abnormal BDNF expression has been observed in
these two areas [15], and conditional knockout of BDNF in
theforebraininducedimpairedlocomotoractivityinrodents
[25].
Locomotor hyperactivity is routinely used as indicator of
“schizophrenia-like” behavior [17–19] and has been found
in adolescent or adult animals experienced neonatal NMDA
receptorblockade[16,26].Ourﬁndingshowedthefeasibility
of assessing BDNF levels in such a developmental rat
model long after the drug administration. On PND 15, the
BDNF expression increased in PFC but not in hippocampus.
However, on PND 42, the upregulated BDNF levels in
PFC returned to normal level, while the BDNF expression
in hippocampus signiﬁcantly increased and sustained from
PND 42 to PND 77. We did not assess the locomotor activity
on PD15, since the preweaning animal is not suitable for
behavioral assessment of schizophrenia model.
Our ﬁndings are consistent with some preclinical and
clinical studies. A previous clinical observation showed
that BDNF protein was increased in hippocampus and
unchanged in PFC of schizophrenia patients [27]. Since
the above tested brain samples of all patients received
antipsychotic treatment before death, the association of the
altered BDNF expressions with schizophrenia pathology or
antipsychotic drug eﬀects remains unknown. Furthermore,
it is not known whether the expression of BDNF in
schizophrenia patients changes at diﬀerent ages. The current
study demonstrates that the BDNF levels in MK-801 treated
rats persisted from PND 42 to PND 77, suggesting that
the abnormal expression patterns of BDNF observed in
schizophrenia patients might not be aﬀected by age during
adolescence and early adulthood. Interestingly, the abnormal
BDNF expression occurred between PND 15 and PND
42, adolescence in rats. This is consistent with clinical
observations that schizophrenia is usually diagnosed at late
adolescence or early adulthood. This plausible coincidence
of schizophrenia age onset and the emergence of the
BDNF increase hints at the association of BDNF expression
and the etiology of schizophrenia. Additionally, there is
evidence that BDNF protein levels may cause changes in
strength of synaptic transmission in hippocampus [28], and
upregulated BDNF levels in hippocampus can induce other
schizophrenia-like behavior [29]. Thus, it is possible that the
locomotor hyperactivity is related with the increased BDNF
in hippocampus but not PFC in the current study.4 Journal of Biomedicine and Biotechnology
The increase of BDNF levels at PFC is probably a
protective response to MK-801 administration induced
cytotoxic insults [26, 30]. The fact that hippocampus is
spared from acute responses to MK-801 treatment suggests
that the alterations of BDNF in adolescence and adulthood
were not remnants of acute responses. Therefore, the BDNF
changes at adolescence and adulthood may have diﬀerent
roles and mechanisms with that of neonatal stage, which
needs further investigations. It could be seen from the
current study that the alterations of BDNF expression and
locomotor activity both persisted from PND 42 to PND
77. The plausible association between changes in behavioral
performance and BDNF expression indicates that regulation
of BDNF expression may be related with pathophysiology of
schizophrenia.
We are aware that there are several limitations of the
c u r r e n ts t u d y .I th a sb e e nr e p o r t e dt h a tB D N Fl e v e l si n
serum are abnormal in patients with schizophrenia [31, 32];
it would be interesting and important to have information
on circulation, BDNF levels in our future studies. The corre-
lations between behavioral deﬁcits and BDNF alterations are
incompletely understood from this study; a more thorough
behavioral proﬁle needs to be performed in the future.
BDNF protein levels alone may not give a complete account
of BDNF/trk B signaling, and the function of BDNF/trk
B signaling may vary among subregions of hippocampus
[33]. mRNA and protein may have diﬀerent developing
trajectories, and diﬀerent transcripts of BDNF may have
diﬀerent development trajectories [34]; more studies for
diﬀerent mRNA transcripts of BDNF need to be carried out.
Theremaybemultipleneurotrophicmoleculesandsignaling
pathways involved in this model; interaction and a network
regulation need to be aware, and investigated as well.
In summary, our present study demonstrates that there
are sustained behavioural deﬁcit and BDNF alterations in
the rat model of schizophrenia induced by neonatal MK-
801 administration. These ﬁndings suggest that altered
expression of BDNF might attribute to schizophrenia and
provide evidence that the patterns of abnormal BDNF
expression may vary at diﬀerent developing stages. Further
experiment needs to elucidate the mechanisms underlying
the age-associated changes of BDNF and the potential roles
of BDNF on abnormal behavior, which may lead to a better
understanding of the pathophysiology of schizophrenia.
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